ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:

3 天之前 · Enhertu is a treatment for breast cancer, advanced stomach cancer, non-small cell lung cancer, and solid tumors with HER2 gene mutations in certain patients. Enhertu may help people with cancer live longer and delay the progression of their disease.

2023年3月7日 · 注射用德曲妥珠单抗，由 阿斯利康 和第一三共联合开发，商品名：优赫得，通用名：Fam-Trastuzumabderuxtecan（T-DXd），医学名：德曲妥珠单抗（ENHERTU），科研代号DS-8201。 这款药物的研究已经经历了很多年，截至目前，德曲妥珠单抗已在全球至少获批5项肿瘤适应证：HER2阳性乳腺癌、胃癌、胃食管交界处癌、HER2低表达乳腺癌、非小细胞肺癌。 德喜曲妥珠单抗 是一款HER2靶向抗体偶联药物（ADC）。 此次获批的适应症为单药用于治疗 …

2025年1月27日 · Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu to an earlier HR-positive treatment setting and broadens the patient population eligible for treatment with a HER2-directed therapy to those with HER2-ultralow ...

2025年1月27日 · ENHERTU (5.4 mg/kg) is approved in more than 75 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization (ISH)+) breast cancer who have received a prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant ...

2025年1月27日 · AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on ...

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or...

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic...

What is ENHERTU? ENHERTU is a prescription medicine used to treat adults who have: Human epidermal growth factor receptor 2 (HER2)-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy for metastatic disease, or